Published in Pharmacoeconomics on August 01, 2012
Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder. Neuropsychiatr Dis Treat (2015) 0.76
US-Based Drug Cost Parameter Estimation for Economic Evaluations. Med Decis Making (2014) 0.75
Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD. BMC Psychiatry (2016) 0.75
What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care (2008) 5.14
Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry (2001) 3.87
National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry (2003) 3.07
A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics (2008) 2.22
Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample. J Am Acad Child Adolesc Psychiatry (1996) 2.10
Stimulant treatment patterns and compliance in children and adults with newly treated attention-deficit/hyperactivity disorder. J Manag Care Pharm (2004) 1.97
Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord (1998) 1.75
Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry (2009) 1.73
Utilization and cost of health care services for children with attention-deficit/hyperactivity disorder. Pediatrics (2001) 1.72
Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood) (2000) 1.70
Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin (2005) 1.66
The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol (2007) 1.61
Social and emotional impairment in children and adolescents with ADHD and the impact on quality of life. J Adolesc Health (2010) 1.50
A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess (2006) 1.49
A review of the economic burden of ADHD. Cost Eff Resour Alloc (2005) 1.39
Societal costs and quality of life of children suffering from attention deficient hyperactivity disorder (ADHD). Eur Child Adolesc Psychiatry (2007) 1.34
How much are Americans willing to pay for a quality-adjusted life year? Med Care (2008) 1.26
Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol (2009) 1.15
A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry (2011) 1.09
Combination pharmacotherapy for adult ADHD. Curr Psychiatry Rep (2006) 1.04
Methylphenidate in children with hyperactivity: review and cost-utility analysis. Pharmacoepidemiol Drug Saf (2001) 0.94
Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model. CNS Drugs (2007) 0.93
Estimation of utilities in attention-deficit hyperactivity disorder for economic evaluations. Patient (2011) 0.90
A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res (2009) 0.88
Healthcare use, social burden and costs of children with and without ADHD in Flanders, Belgium. Clin Drug Investig (2006) 0.88
The cost-effectiveness of atypicals in the UK. Value Health (2008) 0.84
Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years. Child Adolesc Psychiatry Ment Health (2009) 0.83
The pursuit of transparency and quality improvement in cost-effectiveness analysis - a case study in disease-modifying drugs for the treatment of multiple sclerosis. J Manag Care Pharm (2011) 0.82
Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK. Int J Clin Pract (2009) 0.81
Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis. Arthritis Rheum (1999) 0.77
Increased risk for irritable bowel syndrome after acute diverticulitis. Clin Gastroenterol Hepatol (2013) 4.24
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm (2011) 2.25
Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry (2012) 2.14
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison. Appl Health Econ Health Policy (2012) 2.06
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States. J Med Econ (2012) 2.05
The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R). Biol Psychiatry (2005) 2.03
Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol (2006) 1.96
Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology (2008) 1.78
The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care. BMC Pediatr (2012) 1.73
A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med (2012) 1.67
Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study. CNS Drugs (2013) 1.58
Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences. Circulation (2008) 1.39
Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol (2013) 1.35
Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S. Obesity (Silver Spring) (2007) 1.28
Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings. Health Aff (Millwood) (2011) 1.26
Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke (2006) 1.24
Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol (2008) 1.21
Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ (2011) 1.19
Under diagnosis of adult ADHD: cultural influences and societal burden. J Atten Disord (2012) 1.17
Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics (2010) 1.10
Increased risks of developing anxiety and depression in young patients with Crohn's disease. Am J Gastroenterol (2011) 1.10
Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ (2011) 1.10
Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives. Circ Cardiovasc Qual Outcomes (2012) 1.09
Productivity costs associated with cardiometabolic risk factor clusters in the United States. Value Health (2007) 1.08
Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs. Postgrad Med (2012) 1.08
Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. J Med Econ (2012) 1.07
Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment. J Manag Care Spec Pharm (2015) 1.06
Error identification, disclosure, and reporting: practice patterns of three emergency medicine provider types. Acad Emerg Med (2004) 1.04
Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case. Eur Child Adolesc Psychiatry (2013) 1.03
Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health (2012) 1.03
Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther (2009) 1.02
Utilization patterns of stimulants in ADHD in the Medicaid population: a retrospective analysis of data from the Texas Medicaid program. Clin Ther (2012) 1.01
Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study. Health Qual Life Outcomes (2012) 1.01
Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis. Adv Ther (2012) 1.01
Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin (2007) 1.01
Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol (2011) 0.99
Treatment patterns and symptom control in patients with GERD: US community-based survey. Curr Med Res Opin (2009) 0.98
Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010). Curr Med Res Opin (2014) 0.95
Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin (2009) 0.94
Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin (2010) 0.93
Persistence of pharmacological treatment into adulthood, in UK primary care, for ADHD patients who started treatment in childhood or adolescence. BMC Psychiatry (2012) 0.93
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clin Drug Investig (2011) 0.92
The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol (2010) 0.92
Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials. Curr Med Res Opin (2011) 0.92
The decisions regarding ADHD management (DRAMa) study: uncertainties and complexities in assessment, diagnosis and treatment, from the clinician's point of view. Eur Child Adolesc Psychiatry (2011) 0.92
First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study. Breast Cancer Res (2003) 0.91
Estimation of utilities in attention-deficit hyperactivity disorder for economic evaluations. Patient (2011) 0.90
Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med (2011) 0.90
Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol (2009) 0.90
Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. Am J Clin Dermatol (2011) 0.90
Adult ADHD patient experiences of impairment, service provision and clinical management in England: a qualitative study. BMC Health Serv Res (2013) 0.89
Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. CNS Drugs (2012) 0.89
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib. Curr Med Res Opin (2013) 0.89
The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. J Am Acad Dermatol (2011) 0.89
ADHD burden of illness in older adults: a life course perspective. Qual Life Res (2011) 0.89
Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child Adolesc Psychiatry Ment Health (2009) 0.88
Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population. J Occup Environ Med (2006) 0.88
Distinguishing comorbidity and successful management of adult ADHD. J Atten Disord (2012) 0.87
Time course and predictors of health-related quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treated with the methylphenidate transdermal system. J Child Adolesc Psychopharmacol (2010) 0.87
Costs of Parkinson's disease in a privately insured population. Pharmacoeconomics (2013) 0.87
Occupational issues of adults with ADHD. BMC Psychiatry (2013) 0.87
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Pharmacoepidemiol Drug Saf (2012) 0.86
An interim analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) evaluation of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr (2005) 0.86
Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs (2013) 0.86
Adult ADHD: prevalence of diagnosis in a US population with employer health insurance. Curr Med Res Opin (2011) 0.86
Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Curr Med Res Opin (2014) 0.86
A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. J Med Econ (2010) 0.85
Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. Eur J Gastroenterol Hepatol (2009) 0.85
Risks of developing psychiatric disorders in pediatric patients with psoriasis. J Am Acad Dermatol (2012) 0.85
Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin (2010) 0.85
Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis. J Med Econ (2013) 0.84
Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications. J Med Econ (2013) 0.84
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health (2011) 0.84
Unmet needs associated with attention-deficit/hyperactivity disorder in eight European countries as reported by caregivers and adolescents: results from qualitative research. Patient (2015) 0.84
Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy. Int J Cardiol (2012) 0.83
Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children With ADHD. J Atten Disord (2007) 0.83
Management of adult attention deficit hyperactivity disorder in UK primary care: a survey of general practitioners. Health Qual Life Outcomes (2013) 0.83
Development and validation of a claims-based prediction model for COPD severity. Respir Med (2013) 0.83
Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ (2013) 0.82
Use of inhaled corticosteroids and healthcare costs in mild persistent asthma. J Asthma (2007) 0.82
Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes. Diabetes Care (2013) 0.82
Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis. BMC Gastroenterol (2012) 0.82
Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. J Med Econ (2014) 0.82
A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Curr Med Res Opin (2012) 0.82
Concomitant pharmacotherapy of psychotropic medications in EU children and adolescents with attention-deficit/hyperactivity disorder. Drugs R D (2013) 0.82
Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: heterogeneity in parent preferences. Int J Technol Assess Health Care (2011) 0.82
Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin (2007) 0.82
Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis. Curr Med Res Opin (2012) 0.82